Thursday, November 16, 2017 4:21:31 AM
Biggest thing for me was the trial starting soon (after FDA approval) for CAR T to be used as first line treatment instead of chemo etc. That will really expand the market for us. Cost will come down Doc before you start!
Using both cd19 and BCMA CARS 100% response
patient treated with Car T for prostate cancer
CD33 for AML starting at Penn 2018
Then JD expecting near capacity manuf. and further contracts.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM